Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia
F.M.J. DebruyneDepartment of Urology, Academic Hospital Nijmegen, Geert Grooteplein Zuid 16, 426 Afdeling Urologie, 6500 Nijmegen, The Netherlands. [email protected]A A GresD. ArustamovCenter of Urology, Ministry of Health of Republic of Uzbekistan, 700 109 Tashkent, Uzbekistan
ABI
Abstract
No abstract available.